Clinical Trial Detail

NCT ID NCT02343679
Title Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Anne Beaven, MD
Indications

hematologic cancer

Therapies

Ceritinib

Age Groups: adult

Additional content available in CKB BOOST